Know Cancer

forgot password

The Identification of In Vivo Angiogenesis and Fibrosis in Myocardial Infarction Using Positron Emission Tomography.

40 Years
Not Enrolling
Myocardial Infarction, Fibrosis, Neovascularization, Pathologic

Thank you

Trial Information

The Identification of In Vivo Angiogenesis and Fibrosis in Myocardial Infarction Using Positron Emission Tomography.

Integrins are a group of molecules responsible for intercellular adhesion and signalling.
They comprise a superfamily of heterodimeric receptors that are composed of 18 different α
and β subunits. In combination, they can generate 24 different receptor subtypes with a
range of physiological and pathophysiological functions [Takada et al, 2007]. The αvβ3
receptor is an integrin that is found at low levels on mature endothelial cells but is
markedly up regulated on endothelial cells of actively growing blood vessels. It was
previously known as the vitronectin receptor although it was subsequently found to bind many
other ligands including fibrinogen, fibronectin, laminin, thrombospondin, von Willebrand
factor, and certain collagen subtypes. These features are also seen with the αvβ5 integrin
receptor, with both receptors recognising the arginine-glycine-aspartate (RGD) motif present
on these ligands.

1.1.2 Role of αvβ3 and αvβ5 Integrins in Cardiovascular Disease

The expression of αvβ3 and αvβ5 receptors is up regulated in a number of diseased states and
this has been particularly well characterised in the angiogenesis associated with tumour
growth and metastases [Friedlander et al, 1995; Brooks et al, 1994]. However, there are many
potential roles for this integrin pathway in cardiovascular disease including myocardial
infarction, atherosclerosis, restenosis, aortic stenosis and aneurysm disease that have been
relatively unexplored. Myocardial Infarction

After myocardial infarction, there is an intense inflammatory response followed by
angiogenesis and fibrosis. During this time of healing and reparation, there is marked up
regulation of integrins in order to orchestrate efficient myocardial healing. For the αvβ3
and αvβ5 integrin receptors, this reflects both angiogenesis and fibrosis given their ligand
binding properties [van den Borne et al, 2008; Higuchi et al, 2008]. This is at the centre
of early and delayed left ventricular remodelling in the infarct and peri-infarct zone. The
early phase is dominated by angiogenesis to restore vascular integrity and tissue perfusion
with αvβ3 and αvβ5 receptors being up regulated and expressed on activated endothelial cells
within newly forming vessels [Higuchi et al, 2008]. With subsequent myocardial healing and
remodelling, activation of fibroblasts and differentiation into myofibroblasts requires αvβ3
and αvβ5 receptor interactions and is central to the development of fibrosis [van den Borne
et al, 2008]. Maladaptive fibrotic responses and adverse left ventricular remodelling may
underlie the development of heart failure following myocardial infarction. These processes
and pathways may also play a role in the development of myocardial fibrosis in other
conditions such as left ventricular hypertrophy associated with aortic stenosis [Dweck et
al, 2011]. Atherosclerosis and Restenosis

The development of atherosclerosis is due to a complex interplay of oxidised lipid,
inflammatory cell infiltration, and smooth muscle cell migration in the arterial wall. Once
established, atherosclerotic plaques may progress and rupture leading to the clinical
presentations of acute myocardial infarction and stroke. Features associated with plaque
rupture include a thin fibrous cap, lipid-rich pool and intraplaque haemorrhage. Indeed,
plaque rupture is particularly associated with plaque neovascularisation and
vascular-endothelial growth factor expression [Hiyama et al, 2010] suggesting that
instability may be induced by angiogenesis. Thus, up regulation of αvβ3 and αvβ5 receptors
may represent a novel marker of, and potential therapeutic target for [Maile et al, 2010],
plaque vulnerability.

The process of neointimal hyperplasia and restenosis following percutaneous coronary
intervention involves the recruitment of vascular smooth muscle cells. This process is also
dependent on both αvβ3 and αvβ5 receptors and is also a potential target for inhibition of
restenosis [Kokubo et al, 2007].

1.1.3 Fluciclatide

Fluciclatide is a RGD-containing cyclic peptide that has recently been developed as an
18F-radiotracer to detect tumour angiogenesis by positron emission tomography. It is highly
selective for the αvβ3 and αvβ5 receptors with affinities (EC50) of 11.1 and 0.1 nM
respectively with minimal cross reactivity with the αIIbβ3 receptor (EC50 281 nM).
Pre-clinical tumour work has demonstrated that 18F-fluciclatide is taken up by glioblastomas
and that this is suppressed by the anti-angiogenic tyrosine kinase inhibitor, sunitinib,
confirming the specificity of fluciclatide for areas of angiogenesis. It has been assessed
in phase I clinical trials and found to be safe and well tolerated.

1.1.4 Aims

To date, there have been many preclinical studies examining the application of radiotracers
targeting the αvβ3 and αvβ5 integrin receptors. The clinical application of these tracers
has been largely limited to oncology as a method of assessing angiogenesis within tumours.
Here we wish to explore the role of the αvβ3 and αvβ5 receptor radiotracer,
18F-fluciclatide, to assess angiogenesis and fibrosis in two major cardiovascular disease
areas. Specifically, we intend to assess myocardial angiogenesis and remodeling in patients
with recent myocardial infarction. We anticipate that this patient group will have
co-existent aortic atheroma and this will provide us with an opportunistic assessment of
tracer uptake in atherosclerosis. We feel it is important to assess a range of
cardiovascular conditions to determine whether αvβ3 and αvβ5 integrin receptor expression is
particular to certain disease processes. If successful, these preliminary data will permit
the more detailed exploration of specific disease areas and novel therapeutic interventions.
At present, fluciclatide is not licensed or approved for clinical use and is being used here
as an Investigational Agent to explore the pathophysiology of aortic stenosis.


We hypothesise that 18F-fluciclatide can identify the expression of the αvβ3 and αvβ5
integrin receptors in vivo in man in two major cardiovascular disease areas: acute
myocardial infarction and aortic atherosclerosis. Specifically, we hypothesise that
18F-fluciclatide will:

1. Demonstrate selective uptake within the region of myocardial infarction in the early
phase of recovery (1-3 weeks).

2. Bind in both the infarct and remote regions of patients with substantial myocardial
infarction in the later phases of recovery (6-12 weeks)

3. Be taken up into aortic atherosclerotic plaque.



Following acute myocardial infarction, there is intense up regulation of αvβ3 and αvβ5
receptors that initially helps regulate angiogenesis and the restoration of vascular
integrity and tissue perfusion in addition to delayed expression that is associated with the
development of fibrosis within the infarcted myocardium. We will therefore assess patients
two and nine weeks after acute myocardial infarction. Because it will not be possible to
undertake direct histological confirmation of angiogenesis or fibrosis in this population,
we will compare these findings to patients with established collateral coronary blood flow
from a chronic coronary artery occlusion as well as cardiac magnetic resonance imaging of
established and stable myocardial fibrosis.

6.1.1 Study Schedule

On days 14±7 and 63±7 following an acute myocardial infarction, 30 patients will undergo
blood sampling and positron emission and computed tomography scans with 18F-fluciclatide.
Following injection of 18F-fluciclatide, patients will be monitored using our standard
clinical approach, including observation of haemodynamic parameters, and this will continue
throughout their study visit until departure. They will also undergo cardiac magnetic
resonance imaging with assessment of gadolinium perfusion and late enhancement on day 14±7
and again between 6 to 12 months after the myocardial infarction. We will specifically
recruit two equal sized and matched populations of patients (n=15 per group) in whom the
infarct-related artery has been, or has not been, revascularised with percutaneous coronary
intervention. In addition, we will similarly assess, on a single occasion, 10 age and
sex-matched patients with a chronic (>6 months) occlusion of a major epicardial vessel.

Blood samples will be assessed using standard clinical biochemical and haematological
profiles such as full blood count and urea and electrolytes. In addition, markers of cardiac
ischaemia, fibrosis and angiogenesis will be assessed. Additional serum, plasma and DNA will
be stored at -80 degrees Celsius for future potential analyses.

6.1.2 Study Interpretation

Given that the vessels will be fully established, the collateral arteries and any infarcted
myocardium of patients with a chronic occlusion will not express the αvβ3 and αvβ5
receptors, and will act as negative controls. We also anticipate that those with an acute
myocardial infarction and an unrevascularised complete coronary artery occlusion will have
more intensive uptake of 18F-fluciclatide at both day 14 and day 63 because of greater early
neovascularisation and more extensive infarction. Patients with complete revascularisation
are likely to have modest angiogenesis and fibrosis, and we therefore anticipate less
intense 18F-fluciclatide uptake at both time points. Although we will not have a comparator
of histology, the cardiac magnetic resonance imaging will provide us with data on the extent
of the myocardial infarction (day 14) and fibrosis (6 - 12 months), left ventricular
function, degree of myocardial perfusion and presence of microvascular obstruction. We will
also assess the entire infarct group (n=30) to determine whether the extent of
18F-fluciclatide uptake correlates with magnetic resonance measures of left ventricular
function and remodelling following infarction.

We intend to use the images obtained from 10 age and sex matched healthy subjects recruited
from a co-existing study titled 'The identification of in vivo angiogenesis and fibrosis in
aortic stenosis using positron emission tomography' (R&D 2012/R/CAR/23, REC 12/SS/0204).
These will act as negative controls as comparators for healthy myocardium. It is a similar
study involving the use of radiotracer 18F-Fluciclatide in patients with Aortic Stenosis.
These patients will have undergone a single CT-PET scan and an MRI scan with assessment of
late gadolinium enhancement and will have consented for their data to be used in this
current study.


Patients with acute myocardial infarction will have a high prevalence of concomitant aortic
atherosclerosis. In Dr Dweck's Fellowship, we were able to exploit this association and
undertake secondary analyses of 18F-sodium fluoride uptake in aortic and coronary
atherosclerosis [Dweck et al, 2012b]. This generated some highly innovative findings that
informed our understanding of atherosclerosis and the role of calcification.

6.2.1 Study Schedule

We will use the datasets obtained from the patients above to explore the uptake of
18F-fluciclatide within the thoracic aorta. Atherosclerosis will be identified using
computed tomography and magnetic resonance images obtained of the thorax at the time of the
study scans. No additional image acquisition will be required. This will provide pilot data
to inform subsequent dedicated studies focused on acutely inflamed atherosclerotic plaques,
such as patients with recent transient ischaemic attacks or strokes attributable to carotid

Inclusion Criteria:

Patients will be recruited if they are >40 years of age and have sustained a recent large
(plasma troponin I concentration >10 ng/mL; upper limit of normal 0.05 ng/mL) acute
myocardial infarction defined according to the Universal Definition of myocardial
infarction [Thygesen et al, 2007].

We will recruit patients with a major epicardial occlusion that has or has not been
revascularised with percutaneous coronary intervention (n=15 per group). We will also
recruit 10 patients with an angiographically documented chronic (>6 months) proximal
coronary artery occlusion that has not been revascularised but has extensive collateral
coronary blood flow.

Exclusion Criteria:

- A known critical (≥95%) left main stem coronary artery stenosis

- Continued symptoms of angina at rest or minimal exertion

- Atrial fibrillation

- Hepatic failure (Childs-Pugh grade B or C)

- Renal failure (estimated glomerular filtration rate <25 mL/min)

- Women of child-bearing potential.

- Inability to undergo scanning

- Contraindication to magnetic resonance imaging

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

The primary outcome is heart function determined by ejection fraction (in %) 6 months following a heart attack.

Outcome Time Frame:

6 - 12 months

Safety Issue:


Principal Investigator

William SA Jenkins, MBChB

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Edinburgh / NHS Lothian


United Kingdom: Research Ethics Committee

Study ID:




Start Date:

April 2013

Completion Date:

August 2015

Related Keywords:

  • Myocardial Infarction
  • Fibrosis
  • Neovascularization, Pathologic
  • Angiogenesis
  • Fibrosis
  • Myocardial Infarction
  • Imaging
  • CT-PET
  • PET-CT
  • Cardiac MRI
  • Fibrosis
  • Infarction
  • Myocardial Infarction
  • Neovascularization, Pathologic